FDA approves new kinase inhibitor for rare joint tumor

The U.S. FDA has approved pimicotinib (Pimjetmi), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) where surgical removal is problematic. This approval is based on findings from the global phase 3 MANEUVER trial, which demonstrated deep and durable tumor responses and improvements in patient function. This offers a new therapeutic option for a rare and debilitating condition.